Lidocaine Hcl And Epinephrine Injection, Solution
NDC Package 51662-1503-3

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Lidocaine Hcl And Epinephrine injection is lidocaine Hydrochloride and Epinephrine Injection, USP is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection, by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. This formulation utilizes a injection, solution delivery system. Marketed by Hf Acquisition Co Llc, Dba Healthfirst, this product is identified by NDC 51662-1503 and is authorized under FDA application ANDA089646.

Identification & Billing

NDC Package Code
51662-1503-3
Package Description
25 POUCH in 1 CASE / 1 VIAL, MULTI-DOSE in 1 POUCH (51662-1503-2) / 30 mL in 1 VIAL, MULTI-DOSE
Product Code
51662-1503
11-Digit Billing Format
51662150303
RxNorm Crosswalk
  • RxCUI: 1010759 - lidocaine HCl 2 % / EPINEPHrine 1:100,000 Injectable Solution
  • RxCUI: 1010759 - epinephrine 0.01 MG/ML / lidocaine hydrochloride 20 MG/ML Injectable Solution
  • RxCUI: 1010759 - epinephrine (as epinephrine bitartrate) 1:100,000 / lidocaine hydrochloride 2 % Injectable Solution
  • RxCUI: 1010759 - epinephrine 1:100,000 / lidocaine hydrochloride 2 % Injectable Solution

Clinical Specifications

Proprietary Name
Lidocaine Hcl And Epinephrine
Non-Proprietary Name
Lidocaine Hcl And Epinephrine
Substance Name
Epinephrine; Lidocaine Hydrochloride
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
  • Infiltration - Administration that results in substances passing into tissue spaces or into cells.
  • Perineural - Administration surrounding a nerve or nerves.
Active Ingredient(s)
Pharmacologic Class
Usage Information
Lidocaine Hydrochloride and Epinephrine Injection, USP is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection, by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.

Regulatory & Marketing

Labeler Name
Hf Acquisition Co Llc, Dba Healthfirst
Product Type
Human Prescription Drug
FDA Application #
ANDA089646
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-11-2020
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (51662-1503). Click a package code to view its specific billing and regulatory data.

51662-1503-1
30 mL in 1 VIAL, MULTI-DOSE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51662-1503-3 identifies a specific commercial package of 25 pouch in 1 case / 1 vial, multi-dose in 1 pouch (51662-1503-2) / 30 ml in 1 vial, multi-dose of Lidocaine Hcl And Epinephrine, a human prescription drug labeled by Hf Acquisition Co Llc, Dba Healthfirst. This injection, solution is formulated for infiltration; perineural use and contains epinephrine; lidocaine hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hf Acquisition Co Llc, Dba Healthfirst on March 11, 2020. The current certification is valid through December 31, 2026.

How is this Hf Acquisition Co Llc, Dba Healthfirst product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51662150303. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
51662-1503-3
11-Digit CMS (5-4-2)
51662-1503-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.